Main Points:
– TG Therapeutics partners with MaxCyte’s electroporation technology for CAR T cell therapy for autoimmune diseases.
– TG has received Investigational New Drug (IND) clearance for the treatment.
– Phase I trial for multiple sclerosis expected to start in 2025.
Author’s Take:
TG Therapeutics’ collaboration with MaxCyte marks a significant step in the development of advanced cell therapies for autoimmune diseases, with promising plans to initiate clinical trials in the near future. This strategic partnership demonstrates the growing intersection of technology and therapeutic innovation in the field of biotechnology.
Click here for the original article.